Skip to main content
SpringerLink
Log in

Phase I Trials on Anti-hypertensive Drugs

  • Chapter
Early Phase Drug Evaluation in Man

  • 44 Accesses

Abstract

Cardiovascular disease is the major cause of mortality in the western world. Since hypertension has been identified as a potent risk factor for both stroke and myocardial infarction,1,2 it is not surprising that many drugs which reduce blood pressure are already in widespread clinical use, with more under preclinical investigation, or at the stage of Phase I trials. The results from the major hypertension trials confirm that blood pressure reduction lowers the incidence of stroke, even in mild hypertension, and by the percentage expected for a direct relationship between hypertension and stroke.3 However, blood pressure reduction has proved singularly disappointing in prevention of myocardial infarction.4–7

Morals do not forbid making experiments on one’s neighbour or on one’s self. … Among the experiments that may be tried on man, those that can only harm are forbidden, those that are innocent are permissible and those that may do good are obligatory.

Claude Bernard, 1865

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Framingham Study (1971). Systolic versus diastolic blood pressure and risk of coronary heart disease. Am. J. Cardiol., 27, 355–3

    Google Scholar 

  2. Kannel, W. B. (1975). Role of blood pressure in cardiovascular disease: The Framingham study. Angiology, 26, 1–14

    Article  CAS  PubMed  Google Scholar 

  3. Dollery, C. T. (1987). Risk predictor, risk indicator and benefit factors in hypertension. Am. J. Med., 82 (Suppl. 1A), 2–8

    Article  CAS  PubMed  Google Scholar 

  4. Australian Therapeutic Trial in Mild Hypertension (1980). Report by the management committee. Lancet., 1, 1261–7

    Google Scholar 

  5. Hpertension Detection and Follow Up Programme Co-operative Group (1979). Five-year findings of the Hypertension Detection and Follow Up Programme I. Reduction in mortality of persons with high blood pressure, including mild hypertension. J. Am. Med. Assoc., 242, 2562–71

    Article  Google Scholar 

  6. Hypertension Detection and Follow Up Programme Co-operative Group (1982). Five-year findings of the Hypertension Detection and Follow Up Programme III. Reduction in stroke incidence among persons with high blood pressure. J. Am. Med. Assoc., 24, 633–8

    Google Scholar 

  7. Medical Research Council Working Party on mild to moderate hypertension (1985). MRC trial of treatment of mild hypertension: principal results. Br. Med. J., 291, 97–104

    Article  Google Scholar 

  8. Hollifield, J. W., Slaton, P. E. and Liddle, G. W. (1975). Some biochemical consequences of diuretic therapy of low renin essential hypertension. Proceedings of the Third Symposium of Hypertension by UCLA at Boca Raton. In Samblin, M. P. (Ed.), Systemic Effects of Antihypertensive Agents. Stratton International, New York, pp. 131–52

    Google Scholar 

  9. Breckenridge, A. (1966). Hypertension and hyperuricaemia. Lancet, i, 15–17

    Article  Google Scholar 

  10. Murphy, M. B., Lewis, P. J., Kohner, E. M., Schuner, B. and Dollery, C. T. (1982). Glucose intolerance in hypertensive patients treated with diuretic, a fourteen-year follow-up. Lancet, ii, 1293–8

    Article  Google Scholar 

  11. Ames, R. P. (1983). Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies. Am. J. Cardiol., 51, 632–9

    Article  CAS  PubMed  Google Scholar 

  12. Lever, A. F. (1986). Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J. Hyperten., 4, 515–24

    Article  CAS  Google Scholar 

  13. Haeusler, G. (1987). Potential future developments in the field of antihypertensive drugs. Eur. Heart J., 8 (Suppl. M), 135–42

    Article  CAS  PubMed  Google Scholar 

  14. Buckingham, R. E., Clapham, J. C., Coldwell, M. C., Hamilton, T. C. and Howlett, D. R. (1986). Stereo-specific mechanism of action of the novel antihypertensive agent, BRL 34915. Br. J. Pharmacol., 87, 78p

    Google Scholar 

  15. Coldwell, M. C. and Howlett, D. R. (1987). Specificity of action of the novel anti-hypertensive agent, BRL 34915 as a potassium channel activator. Comparison with nicorandil. Biochem. Pharm., 36, 3663–9

    Article  CAS  PubMed  Google Scholar 

  16. Webb, D. J., Manhem, P. J. O., Ball, S. G., Inglis, G., Leckie, B. J., Lever, A. F., Morton, J. J., Robertson, J. I. S., Murray, G. D., Menard, J., Hallett, A., Jones, D. M. and Szelke, M. (1985). A study of the renin inhibitor H142 in man. J. Hyperten., 3, 653–8

    Article  CAS  Google Scholar 

  17. Szelke, M., Leckie, B., Hallett, A. et al. (1982). Potent new inhibitors of renin. Nature, 299, 555–7

    Article  CAS  PubMed  Google Scholar 

  18. Tree, M., Szelke, M., Leckie, B. J. et al. (1985). Renin inhibitors: their use in understanding the role of angiotensin II as a pressor hormone. J. Cardiovasc. Pharmacol, 7 (Suppl. 4), S49–S52

    Article  CAS  PubMed  Google Scholar 

  19. Haegerty, A. M., Donovan, M. A., Castleden, C. M., Pohl, J. F., Patel, L. and Hedger, A. (1981). Influence of cimetidine on pharmacokinetics of propranolol. Br. Med. J., 282, 1917–9

    Article  Google Scholar 

  20. Hodsman, G. P., Isles, C. G., Murray, G. D., Usherwood, T. P., Webb, D. J. and Robertson, J. I. S. (1983). Factors related to the first dose hypotensive effect of captopril: prediction and treatment. Br. Med. J., 284, 832–4

    Article  Google Scholar 

  21. Packer, M. (1989). Combined beta-adrenergic and calcium-entry blockade in angina pectoris. New Engl. J Med., 320, 709–18

    Article  CAS  PubMed  Google Scholar 

  22. Cockcroft, J. R. and Dollery, C. T. (1989). The diuretic dilemma. In Buhler, F. R. and Laragh, J. H. (Eds.), The Handbook of Hypertension, Vol. 13. Elsevier, Amsterdam, in press

    Google Scholar 

  23. Stressman, J. and Ben-Ishay, D. (1980). Chlorthalidone-induced impotence. Br. Med. J., 281, 714

    Article  Google Scholar 

  24. Brodie, B. B. and Reid, W. D. (1967). Some pharmacological consequences of species variation in rates of metabolism. Fed. Proc., 26, 1062–70

    CAS  PubMed  Google Scholar 

  25. Paterson, J. W., Connolly, M. E., Dollery, C. T., Hayes, A. and Cooper, R. G. (1970). The pharmacodynamics and metabolism of propranolol in man. Pharm. Clin., 2, 127–33

    Article  CAS  Google Scholar 

  26. George, C. F., Fenyvesi, T., Connolly, M. E. and Dollery, C. T. (1972). Pharmacokinetics of dextro, laevo and racemic propranolol in man. Eur. J. Clin. Pharm., 4, 74–80

    Article  CAS  Google Scholar 

  27. Keberle, H., Faigle, J. W., Hedwall, P., Riem, W. and Wagner, J. (1973). Plasma concentrations and pharmacological response in animals. In Davies, D. S. and Pritchard, B. N. C. (Eds.), Biological Effects of Drugs in Relation to Their Plasma Concentrations. Macmillan, London, 13–24

    Google Scholar 

  28. Brunner, H. R., Waeber, B. and Nussberger, J. (1983). Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy? Hypertension, 5 (Suppl. 3), 101–7

    CAS  Google Scholar 

  29. Campbell, D. J. (1987). Circulating and tissue angiotensin systems. J. Clin. Invest., 79, 1–6

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Cohen, L. and Kurz, M. D. (1982). Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK421. J. Pharm. Expl. Ther., 220, 63–9

    CAS  Google Scholar 

  31. Biollaz, J., Burnier, M., Turini, G. A. et al. (1981). Three new long acting angiotensin-con verting enzyme inhibitors: relationship between plasma-converting enzyme activity and response to angiotensin I. Clin. Pharmacol. Ther., 29, 668–70

    Article  Google Scholar 

  32. Dollery, C. T., Davies, D. S., Draffan, G. H., Dargie, H. J., Dean, C. R., Reid, J. L., Clare, R. A. and Murray, S. (1976). Clinical pharmacology and pharmacokinetics of Clonidine. Clin. Pharmacol. Ther., 19, 11–17

    CAS  PubMed  Google Scholar 

  33. Bennett, E. D., Barclay, S. A., Davis, A. L. et al. (1984). Ascending aortic blood velocity and acceleration using Doppler ultrasound in the assessment of left ventricular function. Cardiovas. Res., 18, 632

    Article  CAS  Google Scholar 

  34. Ihlen, H., Myhre, E., Amlie, J. P. et al. (1985). Changes in left ventricular stroke volume measured by Doppler echocardiography. Br. Heart J., 54, 378

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Metealf, M. J. and Rawles, J. M. (1989). Stroke distance in acute myocardial infarction: a simple measurement of left ventricular function. Lancet, i, 1371–3

    Google Scholar 

  36. Dargie, H. J., Dollery, C. T. and Daniel, J. (1977). Minoxidil in resistant hypertension. Lancet, ii, 515–18

    Article  Google Scholar 

  37. Kirchheim, H. R. (1976). Systemic arterial baroreceptor reflexes. Physiolog. Rev., 56, 100–76

    CAS  Google Scholar 

  38. Roberts, D. H., Tsao, Y. and Breckenridge, A. M. (1986). The reproducibility of limb flow measurements in human volunteers at rest and after exercise by using mercury in Silastic strain gauge plethysmography under standardised conditions. Clin. Sci., 70, 635–8

    Article  CAS  PubMed  Google Scholar 

  39. Benjamin, N., Cockcroft, J. R., Collier, J. G., Dollery, C. T., Ritter, J. M. and Webb, D. J. (1989). Local inibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J. Physiol., 412, 543–55

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Robinson, B. F. (1978). Assessment of the effects of drugs on the venous system in man. Br. J. Clin. Pharm., 6, 381–6

    Article  CAS  Google Scholar 

  41. Webb, D. J. and Collier, J. G. (1987). Influence of ramipril diacid on the peripheral vascular effects of angiotensin I. Am. J. Cardiol., 59, 45D–9D

    Article  CAS  PubMed  Google Scholar 

  42. Webb, D. J., Benjamin, N. and Vallance, P. (1989). The potassium channel opening drug cromakalim produces arterio-selective vasodilation in the upper limbs of healthy volunteers. Br. J. Clin. Pharm., 27, 757–61

    Article  CAS  Google Scholar 

  43. Kinney, E. L., Trautman, J., Gold, J. A., Vessel, E. S. and Zelis, R. (1981). Under-representation of women in new drug trials. Ann. Int. Med., 95, 495–9

    Article  CAS  PubMed  Google Scholar 

  44. Guidicelli, J. F. and Tillement, J. P. (1977). Influence of sex on drug kinetics in man. Clin. Pharm., 2, 157–66

    Article  Google Scholar 

  45. Bühler, F. R., Burkart, F., Lutold, B. E., Kung, M., Marbet, G. and Pfisterer, M. (1975). Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenic mechanisms in essential hypertension. Am. J. Cardiol., 36, 653–9

    Article  PubMed  Google Scholar 

  46. Cruickshank, J. K. and Beevers, D. G. (1985). Ethnic and geographical differences in blood pressure. In Bulpitt, C. J. (Ed.), Epidemiology of Hypertension. Elsevier, Cambridge, pp. 70–87

    Google Scholar 

  47. Cryer, P. E., Hammond, M. W. and Santiago, J. V. (1976). Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated haemodynamic and metabolic events. New Engl. J. Med., 295, 573–7

    Article  CAS  PubMed  Google Scholar 

  48. Freestone, S. and Ramsay, L. E. (1983). Effect of beta-blockade on the pressor response of coffee plus smoking in patients with mild hypertension. Drugs, 25 (Suppl. 2), 141–5

    Article  Google Scholar 

  49. Klatsky, A. L., Friedman, T. D., Seiglaub, A. B. and Gerard, M. J. (1977). Alcohol consumption and blood pressure: Kaiser Permanente multiphasic health examination data. New Engl. J. Med., 196, 1194–200

    Article  Google Scholar 

  50. Potter, J. F., Watson, R. D. S., Skan, W. and Beevers, D. G. (1986). The pressor and metabolic effects of alcohol in normotensives. Hypertension, 8, 625–31

    Article  CAS  PubMed  Google Scholar 

  51. Potter, J. F., McDonald, I. A. and Beevers, D. G. (1986). Alcohol raises blood pressure in hypertensive patients. J. Hyperten., 4, 435–41

    Article  CAS  Google Scholar 

  52. Bannon, L. T., Potter, J. F., Beevers, D. G., Saunders, J. B., Walters, J. R. E. and Ingram, M. C. (1984). Effect of alcohol withdrawal on blood pressure, plasma renin activity, alldosterone, cortisol and dopamine beta-hydroxylase. Clin. Sci., 66, 659–63

    Article  Google Scholar 

  53. Webb, D. J., Cumming, A. M. M., Leckie, B. J. et al. (1983). Reduction of blood pressure in man with H142, a potent new renin inhibitor. Lancet, 2, 1486–7

    Article  CAS  PubMed  Google Scholar 

  54. Oates, J. A. (1988). Antagonism of antihypertensive drug therapy by nonsteroidal anti-inflammatory drugs. Hypertension, 11 (Suppl. 2), 4–6

    Google Scholar 

  55. Bravo, E. L. (1988). Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension, 11 (Suppl. 2), 7–10

    Google Scholar 

  56. Griffiths, R. R., Bigelow, G. E. and Liebson, I. A. (1986). Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J. Pharmacol. Expl. Ther., 239, 416–25

    CAS  Google Scholar 

  57. Galletly, D. C., Fennelly, M. and Whitwam, J. G. (1989). Does caffeine withdrawal contribute to postoperative headache? Lancet, i, 1335

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept of Clinical Pharmacology, Royal Postgraduate Medical School, London, W12 0NN, UK

    John R. Cockcroft

  2. Dept of Pharmacology and Clinical Pharmacology, St George’s Hospital Medical School, London, SW17 0RE, UK

    David J. Webb

Authors
  1. John R. Cockcroft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. May and Baker Pharmaceuticals Rhône-Poulenc Ltd, Dagenham, RM10 7XS, UK

    John O’Grady MD, FRCP (Medical Director, Visiting Professor of Clinical Pharmacology) (Medical Director, Visiting Professor of Clinical Pharmacology)

  2. University of Vienna, Austria

    John O’Grady MD, FRCP (Medical Director, Visiting Professor of Clinical Pharmacology) (Medical Director, Visiting Professor of Clinical Pharmacology)

  3. Clinical Development Unit 1, The Upjohn Company, Kalamazoo, MI, 49001, USA

    Otto I. Linet MD, PhD (Director) (Director)

Copyright information

© 1990 The editors and contributors

About this chapter

Cite this chapter

Cockcroft, J.R., Webb, D.J. (1990). Phase I Trials on Anti-hypertensive Drugs. In: O’Grady, J., Linet, O.I. (eds) Early Phase Drug Evaluation in Man. Palgrave, London. https://doi.org/10.1007/978-1-349-10705-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-349-10705-6_24

  • Publisher Name: Palgrave, London

  • Print ISBN: 978-1-349-10707-0

  • Online ISBN: 978-1-349-10705-6

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation